Bexarotene monotherapy for patients with refractory Sézary syndrome.
Staib
Gyde
G
Department of Dermatology, University of Ulm, Germany. gyde.staib@t-online.de
Scharffetter-Kochanek
Karin
K
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000077610:Bexarotene; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008297:Male; D008875:Middle Aged; D012751:Sezary Syndrome / Q000188:drug therapy* / Q000473:pathology; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology; D013764:Tetrahydronaphthalenes / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D013764:Tetrahydronaphthalenes; D000077610:Bexarotene